Accession Number : ADA338733
Title : Virus-Targeted Therapeutic for Breast Cancer
Descriptive Note : Annual rept. 15 Jul 96-15 Jul 97
Corporate Author : BOSTON UNIV MA SCHOOL OF MEDICINE
Personal Author(s) : Faller, Douglas V.
PDF Url : ADA338733
Report Date : AUG 1997
Pagination or Media Count : 21
Abstract : We have developed small molecules to alter the transcriptional response of viral genes for the treatment of human breast cancer. The transcriptional activity of certain viral genes, including the Epstein-Barr virus (EBV) Thymidine Kinase (TK) gene, is enhanced by these drugs. Exposure to Arginine Butyrate induces the latent TK gene in EBV-infected cells, resulting in susceptibility to ganciclovir. Our approach initially involves investigation of EBV sequences in breast cancer cell lines and specimens, determination of whether treatment with Arginine Butyrate will induce the viral thymidine kinase gene, and determination in vitro of whether the induction of the TK gene and gene product makes the breast cancer cells now susceptible to ganciclovir. The purpose of this proposal is to explore the association of EBV- infection and breast cancer, and to develop an EBV-based strategy for treating breast cancer.
Descriptors : *VIRUSES, *BREAST CANCER, HUMANS, MOLECULES, ENZYMES, IN VITRO ANALYSIS, GENES, EXPOSURE(PHYSIOLOGY), DRUGS, CELLS(BIOLOGY), DETERMINATION, AMINO ACIDS, HISTOLOGY, MAMMARY GLANDS, BUTYRATES, HERPETIC VIRUSES, PHOSPHORUS TRANSFERASES, LYMPHATIC SYSTEM, THYMIDINES.
Subject Categories : Biochemistry
Medicine and Medical Research
Distribution Statement : APPROVED FOR PUBLIC RELEASE